Diabetes technology

Sustained Follow-up of Automated Insulin Delivery in a Real-World Setting: Results at 2 Years of the French Nationwide Observatory OB2F

Diabetes Technol TherPublished Prospective observational cohort study

Authors' conclusion

In a large nationwide real-world cohort, AID use was associated with noninferior TIR between 12 and 24 months, significant improvements in glycemic outcomes compared with baseline, low rates of treatment discontinuation, and favorable safety outcomes.

Study context

Population
Children and adults with T1D initiating automated insulin delivery (AID) therapy in routine clinical practice, France (OB2F)2,225 with data at M24
Participants
2,741 children
Exposure
Time in range (TIR) at M24 vs M12 of AID use
  • M24n = 2,225
Outcome
TIR (70-180 mg/dL); noninferiority of TIR at M24 vs M12
Follow-up
24 months
Methodological detailsnationwide, real-world, noninferiority (M24 vs M12)
  • Nationwide
  • Real-world
  • Noninferiority (M24 vs M12)

Main finding

As reported in the abstract

TIR · M24 vs M12

Observational data: associations, not effects.

Further findings

OutcomeM24Increase (%)P value
TIR change, M24 vs baseline12.0P < 0.0001
HbA1c, baseline to M24M24 vs M07.1%P < 0.0001
TIR change by baseline HbA1c (<8% vs ≥8%) · M24 — Significant interaction between time of AID use and baseline HbA1c category · TIR remained higher with baseline HbA1c <8%
P < 0.001 · P < 0.0001
  • HbA1c, baseline to M24: M0 7.6%
  • TIR change by baseline HbA1c (<8% vs ≥8%): sensitivity analysis, linear mixed-effects model adjusted for age, sex and diabetes duration

AID discontinuation · M24

AID discontinuation at M24
2.1%

Safety

≥1 severe hypoglycaemia episode over preceding 12 months · M24 vs baseline

Proportions lower at M24 than at baseline

Original publication

Sustained Follow-up of Automated Insulin Delivery in a Real-World Setting: Results at 2 Years of the French Nationwide Observatory OB2F. Diabetes Technol Ther. Published 10 July 2026. doi:10.1177/15209156261465478

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.